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Abstract

Key Points

IMPORTANCE Worldwide, preterm birth (PTB) is the single largest cause of deaths in the perinatal
and neonatal period and is associated with increased morbidity in young children. The cause of PTB is
multifactorial, and the development of generalizable biological models may enable early detection

Question What maternal biological
modalities are associated with preterm
birth (PTB)?
Findings In this diagnostic/prognostic

and guide therapeutic studies.

study of 81 pregnant women from 5

OBJECTIVE To investigate the ability of transcriptomics and proteomics profiling of plasma and

birth cohorts in low- and middle-income

metabolomics analysis of urine to identify early biological measurements associated with PTB.

countries, several correlates of preterm
birth in urine and blood were found to

DESIGN, SETTING, AND PARTICIPANTS This diagnostic/prognostic study analyzed plasma and

be associated with PTB. Although

urine samples collected from May 2014 to June 2017 from pregnant women in 5 biorepository

cohort-specific signatures were present,

cohorts in low- and middle-income countries (LMICs; ie, Matlab, Bangladesh; Lusaka, Zambia; Sylhet,

a machine learning algorithm was able

Bangladesh; Karachi, Pakistan; and Pemba, Tanzania). These cohorts were established to study

to generate a model that was capable of

maternal and fetal outcomes and were supported by the Alliance for Maternal and Newborn Health

predicting PTB across the cohorts.

Improvement and the Global Alliance to Prevent Prematurity and Stillbirth biorepositories. Data were
analyzed from December 2018 to July 2019.

Meaning Results of this study suggest
that most PTBs can be predicted using
blood and urine samples collected early

EXPOSURES Blood and urine specimens that were collected early during pregnancy (median
sampling time of 13.6 weeks of gestation, according to ultrasonography) were processed, stored, and

in the pregnancy, providing
opportunities for interventions.

shipped to the laboratories under uniform protocols. Plasma samples were assayed for targeted
measurement of proteins and untargeted cell-free ribonucleic acid profiling; urine samples were
assayed for metabolites.

+ Supplemental content

MAIN OUTCOMES AND MEASURES The PTB phenotype was defined as the delivery of a live infant

Author affiliations and article information are
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before completing 37 weeks of gestation.
RESULTS Of the 81 pregnant women included in this study, 39 had PTBs (48.1%) and 42 had term
pregnancies (51.9%) (mean [SD] age of 24.8 [5.3] years). Univariate analysis demonstrated functional
biological differences across the 5 cohorts. A cohort-adjusted machine learning algorithm was
applied to each biological data set, and then a higher-level machine learning modeling combined the
results into a final integrative model. The integrated model was more accurate, with an area under
(continued)
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Abstract (continued)

the receiver operating characteristic curve (AUROC) of 0.83 (95% CI, 0.72-0.91) compared with the
models derived for each independent biological modality (transcriptomics AUROC, 0.73 [95% CI,
0.61-0.83]; metabolomics AUROC, 0.59 [95% CI, 0.47-0.72]; and proteomics AUROC, 0.75 [95% CI,
0.64-0.85]). Primary features associated with PTB included an inflammatory module as well as a
metabolomic module measured in urine associated with the glutamine and glutamate metabolism
and valine, leucine, and isoleucine biosynthesis pathways.
CONCLUSIONS AND RELEVANCE This study found that, in LMICs and high PTB settings, major
biological adaptations during term pregnancy follow a generalizable model and the predictive
accuracy for PTB was augmented by combining various omics data sets, suggesting that PTB is a
condition that manifests within multiple biological systems. These data sets, with machine learning
partnerships, may be a key step in developing valuable predictive tests and intervention candidates
for preventing PTB.
JAMA Network Open. 2020;3(12):e2029655. doi:10.1001/jamanetworkopen.2020.29655

Introduction
Preterm birth (PTB) is defined by the World Health Organization as the delivery of a live infant before
the completion of 37 weeks of gestation.1,2 The worldwide rate of PTB in 2014 was estimated to be
10.6% (uncertainty interval, 9.0%-12.0%), with 80% of all cases occurring in South Asia and
sub-Saharan Africa.2 Many risk factors for PTB have been highlighted in previous studies and include
obstetrical (eg, previous PTB and multiple gestation), medical (eg, maternal obesity, diabetes, and
chronodisruption), and external (eg, smoking and maternal stress) conditions.3-9 For example, a
meta-analysis of individual- and population-level attributes among 4.1 million births concluded that
“unknown factors requiring further research to act upon account for ~2/3 of the preterm birth
rate.”10(p13) Unveiling and elucidating the role of early biological antecedents of PTB has been
deemed a necessary step toward developing new diagnostic tests and therapeutic interventions.11-13
Biological investigations into the mechanisms of PTB are complicated, as indicated by accumulating
evidence that distinct patient subpopulations follow divergent biological trajectories.14,15 Given this
heterogeneity, simultaneously studying diverse cohorts is critical for identification of generalizable
biological pathways.16
Recent technological advances have enabled the characterization of a broad range of biological
changes during pregnancy. Biological layers explored include single-cell profiling of signaling
pathways,17 measurements of plasma cell-free ribonucleic acid (cfRNA),18 proteome19,20 and
metabolome21 characterization of the microbiome,14,22 and detailed genomics analysis.23 In addition,
a recent multiomics investigation demonstrated that biological changes during normal pregnancy
involve a number of intricate interactions of biological processes, which can be measured using a
coordinated set of assays.24 The integration of the large, multidimensional data sets generated in a
multiomics setting requires complex machine learning pipelines that will remain robust in the face of
the inconsistent intrinsic properties of these high-throughput assays and cohort-specific variations.15
To our knowledge, this is the first multiomics analysis of term and preterm pregnancies from
multiple cohorts in low- and middle-income countries (LMICs). These cohorts were established using
biorepositories of samples and phenotypic data for studying maternal and fetal outcomes collected
and stored from diverse populations of South Asia and sub-Saharan Africa. The study aimed to
investigate the ability of transcriptomics and proteomics profiling of blood plasma and metabolomics
analysis of urine to identify early biological measurements associated with PTB.
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Methods
Approval was obtained from the Stanford University Institutional Review Board, and ethical
exemptions were sought and obtained independently from the respective country by each birth
cohort supported by the Alliance for Maternal and Newborn Health Improvement (AMANHI) and the
Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) biorepositories. Written informed
patient consent was obtained from each participant in the original cohorts and extends to the
present study. We followed the Transparent Reporting of a Multivariable Prediction Model for
Individual Prognosis or Diagnosis (TRIPOD) reporting guideline. This study analyzed plasma and urine
samples collected from May 2014 to June 2017, and data were analyzed from December 2018 to
July 2019.

Participants and Study Design
The study population comprised pregnant women selected from 5 biorepository-supported cohorts
in Matlab, Bangladesh; Lusaka, Zambia; Sylhet, Bangladesh; Karachi, Pakistan; and Pemba, Tanzania.
No compensation or incentives were provided for participating in this study.
Plasma samples were assayed to measure targeted proteins and cfRNA, and urine samples were
analyzed for metabolites. The cfRNA analysis resulted in 20 659 measurements, the targeted
proteomics assay measured 1002 proteins in plasma, and 6630 metabolites were measured in urine.
The number of measurements of these assays did not correlate with their modularity, as indicated
by the number of principal components needed to account for 90% of the total variance (Figure 1A).
This result highlighted the need for a 2-layer metadimensional integrative approach to prevent the
assays with more measurements to bias the predictive models (eMethods in the Supplement). An
overview of the entire data set was produced by first calculating a correlation network of all available
measurements and then producing a 2-dimensional layout for visualization using the t-SNE25
algorithm (Figure 1B).

Biological Assays
From all AMANHI and GAPPS cohorts, trained phlebotomists collected blood samples for
centrifugation and aliquoting of serum, plasma, and buffy coat for storage and future analyses. In
addition, maternal urine was collected in parallel. Collection and processing of all sample types were
performed according to harmonized operating procedures at all study cohorts. The eMethods in the
Supplement provides details on the biological assays.

Statistical Analysis
Data were analyzed from December 2018 to July 2019. All analyses were performed with R, version
3.6.1 (R Foundation for Statistical Computing). All multivariate modeling was performed with a 2-layer
cross-validation strategy to prevent overfitting of the data and to ensure generalizability. Mixedeffect models were used to account for cohort-specific variations (eMethods in the Supplement). The
analysis is independently reproducible. The measured features from all 3 omics data sets
(transcriptomics, metabolomics, and proteomics); the algorithms and source codes for reproduction
of the results; and an interactive website for visualizing the entire data set, the feature evaluation
scores for PTB and gestational age (GA) at sampling, and the pathway enrichment analysis are
available online (https://nalab.stanford.edu/multiomicsmulticohortpreterm/).
We used linear discriminant analysis and principal component analysis (PCA), respectively, to
create a 2-dimensional representation of the entire cohort with cohort labels as the supervised guide
and without supervised information. To confirm the presence of cohort-specific signatures, we used
random forest analysis. We created models for each patient to estimate GA at the time of sample
collection. To simultaneously optimize the integrative model and test the performance of the model
on previously unseen patients, we applied a cross-validation strategy. To predict PTB (GA at delivery
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<37 weeks), we used a leave-one-out cross-validation procedure to test the models on blinded
participants.

Results
Of the 81 pregnant women included in this study, 39 had PTBs (48.1%) and 42 had term pregnancies
(51.9%). The mean (SD) maternal age was 24.8 (5.3) years. The median sampling time was 13.6 weeks
of gestation, according to ultrasonography (Figure 1A).

Data Quality Assessment
To investigate cohort-specific data signatures, PCA was used to create a 2-dimensional
representation of the entire cohort for each biological modality and all modalities combined
(eFigure 1A in the Supplement). The PCA demonstrated that the largest source of variation in the data
was not driven by fundamental differences between the cohorts. Supervised linear discriminant
analysis26 confirmed the existence of more subtle cohort-specific signatures that were not
statistically significant enough to be visualized in an unsupervised PCA (eFigure 1B in the
Supplement). The presence of cohort-specific signatures was confirmed using random forest

Figure 1. Study Overview
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analysis27 that underwent cross-validation to predict the cohort from which the patient was selected
exclusively on the basis of each biological modality (eFigure 1C in the Supplement).
The impact of sample storage time was quantified with random forest analysis that underwent
cross-validation in which the number of days between sample collection and laboratory analyses was
used as a continuous prediction target. The results were statistically significant (thresholds of P =
1.25762 × 10−01 for transcriptomics, P = 8.83433 × 10−06 for metabolomics, and P = 5.56758 × 10−02
for proteomics) only in the case of the urine metabolomics data set, indicating the potential for
sample degradation over time (eFigure 1D in the Supplement). However, this result did not confound
the design of this study as GA at delivery did not correlate with storage time (r = –0.092; P > .41).

Predictive Modeling of Chronicity of Pregnancy
We built models to estimate GA at the time of sample collection (as a surrogate for the chronicity of
pregnancy) for each patient. A cross-validation strategy was used to simultaneously optimize the
integrative model and test the performance of the model on previously unseen patients. Models built
on all 3 modalities (transcriptomics, metabolomics, and proteomics) as well as the integrated model
were statistically significantly correlated with GA at the time of sample collection (transcriptomics:
1.736089 × 10−03; metabolomics: 8.936983 × 10−23; proteomics: 2.227379 × 10−19; and integrated
model: 8.990768 × 10−22; Bonferroni-adjusted Spearman correlation P < .05) (Figure 2A and B). The
features that most correlated with the progression of pregnancy (Spearman correlation P < .05) are
color-coded in Figure 2C. A cluster of highly correlated metabolomics and proteomics features was
identified that included the trophoblast-derived placental growth factor (PGF). Previous studies have
demonstrated that PGF plays a substantial role in the pathogenesis of preeclampsia but has not been
associated with spontaneous PTB.28,29 Pathway analysis30 of the metabolites in this module
indicated the enrichment of the steroid hormone biosynthesis pathway (Fisher test for pathway
enrichment analysis P < 1.2 × 10−12). The purine metabolism pathway was enriched in an additional
module of metabolites (Fisher test for pathway enrichment analysis P < 1.7 × 10−5). Other proteins
that were included in the model and close to this cluster were PAPP-A (pregnancy-associated plasma
protein A), MMP-7 (matrix metallopeptidase 7), FGF and FGFBP1 (fibroblast growth factors), and
SIGLEC6 (sialic acid binding Ig-like lectin 6), all of which play important roles in placental
development.31-34 An additional cluster of proteins associated with cell migration and localization
was identified by gene ontology analysis (Protein Analysis Through Evolutionary Relationships
overrepresentation P < 10 × 10−7).
To further highlight the interplay between plasma proteins and urine metabolites, we
developed a random forest model to estimate the PGF levels of each patient using only the urine
metabolomics data set (eFigure 2 in the Supplement). Overall, this analysis highlighted the potential
for biological profiling for estimating GA during pregnancy (a substantial challenge in LMICs) and the
use of urine-based metabolite biomarkers as low-cost surrogates for models developed through
multiomics analysis.

Predictive Modeling of PTB
For prediction of PTB (GA at delivery <37 weeks), we used a leave-one-out cross-validation procedure
to test the models on blinded participants. Before training the model using the entire data set, the
feature space was limited to the top features in the cohort that corresponded to the blinded sample
based on univariate testing. Overall, the models relied on a subset of all available features. The
median number of features used by the models during cross-validation was 36 for transcriptomics,
35 for metabolomics, and 9 for proteomics. To combine predictions from each model, we developed
an additional integration layer to produce the final weighted probabilities for statistical testing. The
integrated model was more accurate than the model for each independent modality (Figure 3A). The
mean area under the receiver operating characteristic curve (AUROC) and 95% CI for each modality
were as follows: transcriptomics (AUROC, 0.73; 95% CI, 0.61-0.83), metabolomics (AUROC, 0.59;
95% CI, 0.47-0.72), proteomics (AUROC, 0.75; 95% CI, 0.64-0.85), and integrated (AUROC, 0.83;
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95% CI, 0.72-0.91) (Figure 3A). eFigure 3 in the Supplement provides a comparison against other
machine learning strategies applied to the same data set (support vector regression AUROC, 0.57;
random forest AUROC, 0.66; lasso AUROC, 0.68; Gaussian process AUROC, 0.71; supervised learning
cohort-adjusted model AUROC, 0.83; merging AUROC, 0.71; stacked generalization AUROC, 0.76;
data integration cohort-adjusted model AUROC, 0.83). In an independent analysis, this same pipeline
was used to model participants who were randomly assigned to case and control groups, confirming
that the findings presented in Figure 3 did not result from model overfitting (transcriptomics AUROC,
0.54; metabolomics AUROC, 0.50; proteomics AUROC, 0.50; integrated AUROC, 0.50) (eFigure 4
in the Supplement).
Field workers were trained to collect detailed phenotypic and demographic data from the
women and their families through scheduled household visits during pregnancy and postpartum.
Clinical covariates were manually harmonized across all 5 cohorts. Of all the variables collected, only
the weight of the baby and GA at delivery were statistically significantly correlated with the final
outcome of the model predicting PTB (Spearman correlation = 0.73). (eFigure 5 and eTable in the
Supplement). This finding confirmed that the model was not confounded by the other measured
clinical covariates.

Figure 2. Prediction of Gestational Age (GA) at the Time of Sample Collection
A Per-modality hypothesis testing
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patients. Models built on all 3 modalities
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the integrated model were statistically significantly
correlated with GA at the time of sample collection
(Bonferroni-adjusted Spearman correlation P < .05). B,
The correlation between GA at the time of sample
collection and the estimated values on the blinded
samples are shown. The shaded area represents the
95% CI. C, The features correlated with the
progression of pregnancy (Spearman correlation
P < .05) are color-coded according to biological
modality. FGF indicates fibroblast growth factor;
IGSF3, immunoglobulin superfamily member 3;
PAPP-A, pregnancy-associated plasma protein A; PGF,
placental growth factor; and SIGLEC6, sialic acid
binding Ig-like lectin 6.
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Given the statistically significant differences observed across various cohorts, we used mixedeffect models (with each cohort encoded as a random effect) to compare the distribution of each
measurement between term pregnancies and PTBs (Figure 3B). Top features were contained within
2 correlated modules: (1) an inflammatory module, which included interleukin 6 (IL-6), IL-1 receptor
antagonist (IL-1RA, a regulatory member of the IL-1 family whose expression is induced IL-1β under
inflammatory conditions35,36), granulocyte colony-stimulating factor (G-CSF), retinoic acid receptor
responder 2 (RARRES2), and chemokine ligand 3 (CCL3), and (2) a metabolomic module, which
primarily consisted of urine metabolites enriched for glutamine and glutamate metabolism (Fisher
test for pathway enrichment analysis P < 4.4 × 10−9)30 and valine, leucine, and isoleucine
biosynthesis pathways (P < 7.3 × 10−6).37
The presence of inflammatory mediators among the features correlated with PTB is consistent
with finding in previous studies that suggested dysfunctional immune adaptations during pregnancy
was central to the pathogenesis of PTB.38,39 However, the predictive model also highlighted a set of
proteomic features with no known inflammatory properties that were correlated with features from
the inflammatory module. These proteins included protein-arginine deiminase type II (PADI2), a
peptidylarginine deiminase that is responsible for protein citrullination and implicated in parturition
and sensing infections40,41; transferrin receptor (TfR), which is implicated in iron transport;
angiopoietin-like 4 (ANGPTL4), which regulates glucose homeostasis and lipid metabolism42; and
RARRES2, an adipokine that is increased in metabolic syndrome and gestational diabetes.43,44
To ascertain whether observed correlations between these proteins and the inflammatory
module reflected biologically relevant inflammatory properties, we examined the capacity of each of
these factors to stimulate human peripheral blood leukocytes using an ex vivo mass cytometry

Figure 3. Predictive Modeling of Preterm Birth (PTB)
A ROC analysis for prediction of preterm birth
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expression is induced IL-1β under inflammatory conditions; granulocyte colonystimulating factor [G-CSF]; retinoic acid receptor responder protein 2 [RARRES2];
chemokine ligand 3 [CCL3]; angiopoietin-like 4 [ANGPTL4]; protein-arginine deiminase
type II [PADI2]; and transferrin receptor [TfR]) and a metabolomic module (which was
enriched for glutamine and glutamate metabolism [Fisher test for pathway enrichment
analysis P < 4.4 × 10−9] and valine, leucine, and isoleucine biosynthesis pathways [P < 7.3
× 10−6]).
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assay.45 The activity of major intracellular signaling responses previously17 implicated in maternal
immune adaptations during pregnancy was assessed at baseline and after a 15-minute stimulation in
major innate and adaptive immune cell types (eMethods in the Supplement). As expected, robust
and cell-specific signaling responses along the JAK/STAT and MyD88 signaling pathways were
observed in classical monocytes (CMC) after stimulation with known proinflammatory cytokines,
including IL-6 (mean [SD] pSTAT3 ArcSinh ratio over endogenous signal, 2.64 [0.22]; false discovery
rate [FDR]–adjusted vs unstimulated P < 1.0 × 10−6), G-CSF (mean [SD] pSTAT5 ArcSinh ratio over
endogenous signal, 0.42 [0.12]; P = .007), and CCL3 (mean [SD] pCREB ArcSinh ratio over
endogenous signal, 0.35 [0.09]; P < 1.0 × 10−6) (eFigures 6 and 7 and the eMethods in the
Supplement). Stimulation with PADI2 activated the key elements of the MyD88 pathway, including
P38 (mean [SD] ArcSinh ratio over endogenous signal, 0.91 [0.52]; FDR-adjusted vs unstimulated P =
.007), MK2 (mean [SD] ArcSinh ratio over endogenous signal, 0.38 [0.10]; P = .002), and NFkB
(mean [SD] ArcSinh ratio over endogenous signal, 0.14 [0.03]; P = .009), in monocytes, although
little or no signaling responses were observed after stimulation with ANGPTL4, TfR, or RARRES2.
We also tested whether stimulation with the most informative proteomic features of the
predictive model of PTB would alter the effector function of circulating immune cells. To this end, we
quantified the intracellular expression of select cytokines in circulating immune cells that were
stimulated with the target proteins for 4 hours. In addition to the expected cytokine responses after
exposure to CCL3, IL-6, and G-CSF, the results show that PADI2 and ANGPTL4 stimulated
proinflammatory cytokine production in CMC (mean [SD] frequency of PADI2-stimulated IL-1β +
CMC: 18.66 [1.93], FDR-adjusted vs unstimulated P < 1.0 × 10−6; mean [SD] frequency of PADI2stimulated IL-6 + CMC: 8.01 [1.47], P = 1.0 × 10−6; mean [SD] frequency of PADI2-stimulated TNF +
CMC: 7.43 [1.44], P = 1.0 × 10−6) (eFigure 8 and eMethods in the Supplement).
In contrast, stimulation with RARRES2 or TfR elicited little intracellular cytokine responses
(mean [SD] frequency of RARRES2-stimulated IL-1β + CMC: 5.63 [0.25], FDR-adjusted vs
unstimulated P < 1.0 × 10−6; mean [SD] frequency of TfR-stimulated IL-1β + CMC: 2.25 [0.66], P = .16).
These results provide evidence of the potential communication between different biological systems
and add new elements to the complex pathogenesis of preterm birth. Furthermore, the results
suggest that PADI2, in conjunction with other inflammatory cytokines (such as IL-1β), may
exacerbate proinflammatory innate immune responses during PTBs, thereby playing a role in the
early onset of labor.

Discussion
To our knowledge, this study is the first multicohort and multiomics analyses of term and preterm
birth conducted in LMICs through use of biorepository samples from relevant geographies in a
harmonized fashion. The plasma and urine samples were collected, processed, stored, and shipped
to the laboratories under uniform protocols. In this proof-of-concept study, a machine learning
approach was implemented for quality control, analysis of the timing of pregnancy, and prediction of
PTB. Cohort-specific signatures were observed in all cohorts, and data quality was consistent across
all modalities.
The prediction of GA at the time of sample collection was driven by an internally correlated
module of placenta-related plasma proteins and urine metabolites. Correlations within this module
provided an excellent example of leveraging multiomics data for identification of low-cost surrogates
in an accessible biological sample (in this case, urine) for an otherwise complex plasma-based
measurement with direct applications in LMICs. Accurate prediction of GA through laboratory testing
of blood or urine, if validated in larger and more diverse cohorts, has the potential for widespread
implementation in settings in which ultrasonography-based GA dating is not available or is
impractical.
Prediction of PTB using a multiomics model adjusted for each cohort resulted in an AUROC of
0.83. The sparse nature of the developed methods indicated the possibility of developing simplified
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models in a validation cohort for scalable analysis of larger cohorts. Mixed-effect modeling revealed
several features of interest. The top-ranked features, including IL-1RA, pointed to promising antiinflammatory therapy candidates that were under active development.46 Although the prediction of
GA at the time of sample collection was consistent across all 5 cohorts, models for prediction of PTB
required cohort-specific adjustments. This finding is consistent with that in previous publications
that indicated that, although the normal chronicity of pregnancy may be shared across populations,
pathological pregnancies are likely to be population-specific.47,48
Each multiomics data set differed not only across the subcohorts but also in terms of their size
and internal complexities. Therefore, we used a 2-step machine learning strategy in which a model
was first built on each omics data set and then combined for final predictions. This approach
prevented large untargeted data sets from overwhelming small yet carefully targeted assays that
could have a similar or even more discriminatory information content. This approach resulted in an
increase in predictive power and improved interpretability of the results.
In the present study, the predictive accuracy for PTB was augmented by combining various
omics data sets, which was consistent with previous studies suggesting that PTB was a condition
manifesting within multiple biological systems.18,49-52 Observed differences between cohorts also
highlighted that the causes of PTB may be associated with varying environmental and socioeconomic
factors.53 From a biological standpoint, examination of individual components of the multiomics
model emphasized the role of inflammation in the pathobiological features of PTB. As such,
inflammatory cytokines previously shown to be elevated in PTBs, including IL-6 and IL-1RA (often
considered as a surrogate marker of IL-1β expression54) were among the most informative features
of the multiomics model.55 These cytokines were integrated within a broader inflammatory module
that revealed novel factors associated with preterm labor with previously unsuspected properties
(eg, PADI2). In neutrophils, citrullination of histones by PADI2 is an important step in the formation of
neutrophil extracellular traps, a defensive immunity tool that allows neutrophils to trap and kill
bacteria.56-60 Increased soluble PADI2 observed in PTBs may potentially reflect heightened
inflammatory responses to a bacterial pathogen, consistent with an infectious cause for PTB. We
show that soluble PADI2 can also directly activate proinflammatory signaling pathways and cytokine
production in classical monocytes, highlighting a synergistic mechanism that may further enhance
the inflammatory state of PTB.

Strengths and Limitations
This study had several strengths. First, the AMANHI and GAPPS biorepositories used accurate early
trimester ultrasonography scans for GA dating. Second, urine and plasma specimens were collected,
processed, and transported in a harmonized manner. All samples underwent a single freeze-thaw
cycle only at Stanford University before final processing and analysis. Third, the machine learning
strategy used was able to detect patterns that were generalizable across cohorts.
This study also had several limitations. First, it used a small sample size compared with the
number of measurements (which we accounted for through a rigorous 2-step cross-validation
process). Therefore, reproduction of these results in larger and more diverse cohorts remains a major
priority for our future efforts. For reproduction of these results to be successful, the validation of a
reduced model with increased scalability will be a key step. Second, given the exploratory nature of
this study, the cohort was clinically homogeneous (eTable and eFigure 2 in the Supplement), which
limits the generalizability of the results to real-world heterogeneous populations. Therefore, a future
area of investigation is the direct integration of clinical covariates into the predictive models61 to
increase the generalizability in data sets with diverse phenotypes.

Conclusions
This diagnostic/prognostic study found that, in LMICs and high PTB settings, major biological
adaptations during pregnancy may follow a generalizable model, but the biological signals that
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correlate with or are potentially associated with PTB can be detected using robust machine learning
algorithms. In addition, this study demonstrated that a multiomics approach has the potential to
both improve and help identify low-cost predictive surrogates in accessible biological samples for
LMICs. Research to expand this analysis to a larger patient population and to broader cohorts and
omics platforms are already under way. The data sets, together with state-of-the-art machine
learning partnerships,62 will be a key step in developing valuable predictive tests and intervention
candidates to tackle the long-term clinical challenge of preventing PTB.
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